In SWOG S1801 study presented by Dr. Sapna Patel, #neoadjuvant treatment (NAT) with #pembrolizumab showed a significant EFS benefit compared with #adjuvant (AT) pembrolizumab in high-risk resectable #melanoma. In this phase II trial, EFS was significantly higher on NAT compared to AT pembrolizumab (HR=0.59, p=0.0015,) in resected stage III-IV melanoma. Among 313 patients enrolled in the study, 36 deaths were reported (NAT=14, AT=22); however overall survival (OS) data was immature at time of presentation.
.png)